Farnesyl Transferase
Ftase

Farnesyltransferase is one of the three enzymes in the prenyltransferase group. Farnesyltransferase's targets include members of the Ras superfamily of small GTP-binding proteins critical to cell cycle progression.

Farnesyltransferase inhibitors (FTIs) are small-molecule inhibitors that selectively inhibit farnesylation of a number of intracellular substrate proteins such as Ras. Farnesyl transferase inhibitors (FTIs) represent a new class of signaling inhibitors that is emerging in the clinical arena of hematologic malignancies and that may inhibit critical growth and survival signals. FTIs are a class of experimental cancer drugs that target protein farnesyltransferase with the downstream effect of preventing the proper functioning of the Ras (protein), which is commonly abnormally active in cancer.
### Farnesyl Transferase Inhibitors & Antagonists

<table>
<thead>
<tr>
<th>Inhibitor</th>
<th>Cat. No.</th>
<th>Description</th>
<th>Purity</th>
<th>Clinical Data</th>
<th>Size</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ABT-100</strong></td>
<td>HY-119257</td>
<td>ABT-100 is a potent, highly selective and orally active farnesyltransferase inhibitor.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>BMS-214662</strong></td>
<td>HY-16111</td>
<td>BMS-214662 is a potent and selective farnesyl transferase inhibitor with potent antitumor activity with an IC₅₀ of 1.35 nM.</td>
<td>99.59%</td>
<td>Phase 1</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td><strong>FGTI-2734</strong></td>
<td>HY-128350</td>
<td>FGTI-2734 is a RAS C-terminal mimetic dual farnesyltransferase (FT) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀ of 250 nM and 520 nM for FT and GGT-1, respectively.</td>
<td>98.02%</td>
<td>No Development Reported</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td><strong>FGTI-2734 mesylate</strong></td>
<td>HY-128350A</td>
<td>FGTI-2734 mesylate is a RAS C-terminal mimetic dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitor with IC₅₀ of 250 nM and 520 nM for FT and GGT, respectively.</td>
<td>98.73%</td>
<td>No Development Reported</td>
<td>10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg</td>
</tr>
<tr>
<td><strong>FTI-276</strong></td>
<td>HY-15873</td>
<td>FTI-276 is a protein farnesyl transferase (PFT) inhibitor with IC₅₀ of 0.9 and 0.5 nM for Plasmodium falciparum and human.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>FTI-276 TFA</strong></td>
<td>HY-15873A</td>
<td>FTI-276 TFA is a protein farnesyl transferase (PFT) inhibitor with IC₅₀ of 0.9 nM and 0.5 nM for Plasmodium falciparum and human, respectively.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>FTI-2148</strong></td>
<td>HY-118916</td>
<td>FTI-2148 is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀ of 1.4 nM and 1.7 μM, respectively.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>FTI-2148 diTFA</strong></td>
<td>HY-118916A</td>
<td>FTI-2148 diTFA is a RAS C-terminal mimetic dual farnesyl transferase (FT-1) and geranylgeranyl transferase-1 (GGT-1) inhibitor with IC₅₀ of 1.4 nM and 1.7 μM, respectively.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>FTI-2153</strong></td>
<td>HY-123242</td>
<td>FTI-2153 is a potent and highly selective inhibitor of farnesyltransferase (FTase), with an IC₅₀ of 1.4 nM. FTI-2153 is &gt;3000-fold more potent at blocking H-Ras (IC₅₀ 10 nM) than Rap1A processing. Anti-cancer activity.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
<tr>
<td><strong>FTI-277</strong></td>
<td>HY-15872</td>
<td>FTI-277 is an inhibitor of farnesyl transferase (FTase), a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling.</td>
<td>&gt;98%</td>
<td>No Development Reported</td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

**Contact Information:**
Tel: 609-228-6898  Fax: 609-228-5909  Email: sales@MedChemExpress.com
FTI-277 hydrochloride

FTI-277 hydrochloride is an inhibitor of farnesyl transferase (FTase), a highly potent Ras CAAX peptidomimetic which antagonizes both H- and K-Ras oncogenic signaling. FTI-277 hydrochloride can inhibits hepatitis delta virus (HDV) infection.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

L-778123 hydrochloride (L-778,123 hydrochloride)

L-778123 hydrochloride is an inhibitor of FPTase and GGPTase-I with IC50 of 2 nM and 98 nM in enzyme inhibition determination.

Purity: 99.64%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Lapaquistat acetate (TAK-475)

Lapaquistat acetate (TAK-475) is a squalene synthase inhibitor, blocking the conversion of farnesyl diphosphate (FPP) to squalene.

Purity: >99.0%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg

Lonafarnib (Sch66336)

Lonafarnib is an orally bioavailable farnesyl protein transferase (FPTase) inhibitor for H-ras, K-ras and N-ras with IC50 of 1.9 nM, 5.2 nM and 2.8 nM, respectively. Lonafarnib has anti-hepatitis delta virus (HDV) activities.

Purity: 98.67%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 1 mg, 10 mg

Manumycin A

Manumycin A is an antibiotic. Manumycin A acts as a selective, competitive inhibitor of protein farnesyltransferase (FTase) with respect to farnesylpyrophosphate (K_i =1.2 μM), and as a noncompetitive inhibitor with respect to the Ras protein.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Prenyl-IN-1

Prenyl-IN-1 is a protein prenylation inhibitor, especially a geranylgeranyltransferase (GGT) or a farnesyltransferase (FT) inhibitor, exhibiting potent activity against oxidative stress, and particularly in the treatment of Parkinson’s Disease.

Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Purity: 99.89%
Clinical Data: Phase 3
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg
YM-53601 free base  

YM-53601 free base is a squalene synthetase inhibitor which suppresses lipogenic biosynthesis and lipid secretion in rodents.

<table>
<thead>
<tr>
<th>Purity:</th>
<th>&gt;98%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Data:</td>
<td>No Development Reported</td>
</tr>
<tr>
<td>Size:</td>
<td>1 mg, 5 mg</td>
</tr>
</tbody>
</table>

Cat. No.: HY-100313